These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 18499699)
21. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis. Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578 [TBL] [Abstract][Full Text] [Related]
22. [Role of suindac in the treatment of familial adenomatous polyposis coli]. Landauer S; Halimi C; Caulin C; Bergmann JF Therapie; 1999; 54(6):675-82. PubMed ID: 10709439 [TBL] [Abstract][Full Text] [Related]
23. Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam. Ertem FU; Zhang W; Chang K; Mohaiza Dashwood W; Rajendran P; Sun D; Abudayyeh A; Vilar E; Abdelrahim M; Dashwood RH Int J Cancer; 2017 Jan; 140(2):460-468. PubMed ID: 27706811 [TBL] [Abstract][Full Text] [Related]
24. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients. Koornstra JJ; Rijcken FE; Oldenhuis CN; Zwart N; van der Sluis T; Hollema H; deVries EG; Keller JJ; Offerhaus JA; Giardiello FM; Kleibeuker JH Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1608-12. PubMed ID: 16030090 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse. Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222 [TBL] [Abstract][Full Text] [Related]
26. The role of sulindac in familial adenomatous polyposis patients with ileal pouch polyposis. Ho JW; Yuen ST; Chung LP; So HC; Kwan KY Aust N Z J Surg; 1999 Oct; 69(10):756-8. PubMed ID: 10527361 [No Abstract] [Full Text] [Related]
27. Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis. Keller JJ; Offerhaus GJ; Drillenburg P; Caspers E; Musler A; Ristimäki A; Giardiello FM Clin Cancer Res; 2001 Dec; 7(12):4000-7. PubMed ID: 11751493 [TBL] [Abstract][Full Text] [Related]
28. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial. Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131 [TBL] [Abstract][Full Text] [Related]
30. Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis. Ignatenko NA; Besselsen DG; Roy UK; Stringer DE; Blohm-Mangone KA; Padilla-Torres JL; Guillen-R JM; Gerner EW Nutr Cancer; 2006; 56(2):172-81. PubMed ID: 17474863 [TBL] [Abstract][Full Text] [Related]
32. Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Rice PL; Kelloff J; Sullivan H; Driggers LJ; Beard KS; Kuwada S; Piazza G; Ahnen DJ Mol Cancer Ther; 2003 Sep; 2(9):885-92. PubMed ID: 14555707 [TBL] [Abstract][Full Text] [Related]
33. BID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflammatory drugs. Leibowitz B; Qiu W; Buchanan ME; Zou F; Vernon P; Moyer MP; Yin XM; Schoen RE; Yu J; Zhang L Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16520-5. PubMed ID: 25368155 [TBL] [Abstract][Full Text] [Related]
34. Suppression of tumorigenesis in the Apc(min) mouse: down-regulation of beta-catenin signaling by a combination of tea plus sulindac. Orner GA; Dashwood WM; Blum CA; Díaz GD; Li Q; Dashwood RH Carcinogenesis; 2003 Feb; 24(2):263-7. PubMed ID: 12584176 [TBL] [Abstract][Full Text] [Related]
35. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Keller JJ; Offerhaus GJ; Polak M; Goodman SN; Zahurak ML; Hylind LM; Hamilton SR; Giardiello FM Gut; 1999 Dec; 45(6):822-8. PubMed ID: 10562579 [TBL] [Abstract][Full Text] [Related]
36. Sulindac modulates secreted protein expression from LIM1215 colon carcinoma cells prior to apoptosis. Greening DW; Ji H; Kapp EA; Simpson RJ Biochim Biophys Acta; 2013 Nov; 1834(11):2293-307. PubMed ID: 23899461 [TBL] [Abstract][Full Text] [Related]
37. Response of Apc(min) and A33 (delta N beta-cat) mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Orner GA; Dashwood WM; Blum CA; Díaz GD; Li Q; Al-Fageeh M; Tebbutt N; Heath JK; Ernst M; Dashwood RH Mutat Res; 2002 Sep; 506-507():121-7. PubMed ID: 12351151 [TBL] [Abstract][Full Text] [Related]
38. Sulindac in familial adenomatous polyposis. Levy R N Engl J Med; 2002 Aug; 347(8):615. PubMed ID: 12192027 [No Abstract] [Full Text] [Related]
39. Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+)mice. Chiu CH; McEntee MF; Whelan J Prostaglandins Leukot Essent Fatty Acids; 2000 May; 62(5):269-75. PubMed ID: 10883057 [TBL] [Abstract][Full Text] [Related]
40. Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. Davis JS; Kanikarla-Marie P; Gagea M; Yu PL; Fang D; Sebastian M; Yang P; Hawk E; Dashwood R; Lichtenberger LM; Menter D; Kopetz S BMC Cancer; 2020 Sep; 20(1):871. PubMed ID: 32912193 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]